Nanjing Chengong Pharmaceutical Co. Ltd.

Primary Objective: To investigate the bioequivalence of the test formulation (160 mg megestrol acetate dispersible tablets) developed by Nanjing Chengong Pharmaceutical Co., Ltd. and the reference formulation (160 mg megestrol acetate tablets, licensed by PharmaSwiss?eská republika s.r.o., trade name: Megace®) in male healthy study participants under fasting and fed conditions. Secondary Objective: To investigate the safety of the test formulation (160 mg megestrol acetate dispersible tablets) and the reference formulation (160 mg megestrol acetate tablets, licensed by PharmaSwiss?eská republika s.r.o.) in male healthy study participants.

Main purpose: Using Iguratimod tablets (specification: 25 mg) produced by Nanjing Chengong Pharmaceutical Co., Ltd. as the test preparation, and using Iguratimod tablets (trade name: Edexin, specification: 25 mg) certified by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation, a human bioequivalence test was conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Amoxicillin-clavulanate potassium dry suspension produced by Nanjing Chengong Pharmaceutical Co., Ltd. was used as the test preparation, and amoxicillin-clavulanate potassium dry suspension produced by SmithKline Beecham Limited was used as the reference preparation. The bioequivalence of the two preparations in humans was evaluated through a single-center, randomized, open-label study.